Absence of pharmacokinetic and pharmacodynamic interactions between almorexant and warfarin in healthy subjects

Drugs in R and D

Volumn 13, Issue 2, 2013, Pages 145-151

  Dingemanse, Jasper ^a   Hoever, Petra ^a  

^a ACTELION PHARMACEUTICALS LTD   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALMOREXANT; WARFARIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLEEDING; BLOOD SAMPLING; HUMAN; HUMAN EXPERIMENT; INTERNATIONAL NORMALIZED RATIO; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PHARMACODYNAMICS; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; SINGLE DRUG DOSE;

ACETAMIDES; ADULT; ANTICOAGULANTS; CROSS-OVER STUDIES; DRUG INTERACTIONS; FACTOR VII; HEALTHY VOLUNTEERS; HUMANS; HYPNOTICS AND SEDATIVES; INTERNATIONAL NORMALIZED RATIO; ISOQUINOLINES; MALE; WARFARIN;

EID: 84879697811     PISSN: 11745886     EISSN: 11796901     Source Type: Journal    
DOI: 10.1007/s40268-013-0017-5     Document Type: Article

References (22)

1. de Lecea L, Kilduff TS, Peyron C, Gao X, Foye PE, Danielson PE, et al. The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. Proc Natl Acad Sci USA. 1998;95:322-7. (Pubitemid 28103952)
2. Sakurai T, Amemiya A, Ishii M, Matsuzaki I, Chemelli RM, Tanaka H, et al. Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell. 1998;92:573-85. (Pubitemid 28101119)
3. Cao M, Guilleminault C. Hypocretin and its emerging role as a target for treatment of sleep disorders. Curr Neurol Neurosci Rep. 2011;11:227-34.
4. Nattie E, Li A. Central chemoreception in wakefulness and sleep: evidence for a distributed network and a role for orexin. J Appl Physiol. 2010;108:1417-24.
5. Tsujino N, Sakurai T. Orexin/hypocretin: a neuropeptide at the interface of sleep, energy homeostasis, and reward system. Pharmacol Rev. 2009;61:162-76.
6. Scammell TE, Winrow CJ. Orexin receptors: pharmacology and therapeutic opportunities. Annu Rev Pharmacol Toxicol. 2011;51:243-66.
7. Coleman PJ, Renger JJ. Orexin receptor antagonists: a review of promising compounds patented since 2006. Expert Opin Ther Pat. 2010;20:307-24.
8. Brisbare-Roch C, Dingemanse J, Koberstein R, Hoever P, Aissaoui H, Flores S, et al. Promotion of sleep by targeting the orexin system in rats, dogs and humans. Nat Med. 2007;13:150-5.
9. Hoever P, de Haas S, Winkler J, Schoemaker RC, Chiossi E, van Gerven J, Dingemanse J. Orexin receptor antagonism, a new sleep-promoting paradigm: an ascending single-dose study with almorexant. Clin Pharmacol Ther. 2010;87:593-600.
10. Hoever P, Dorffner G, Beneš H, Penzel T, Danker-Hopfe H, Barbanoj MJ, et al. Orexin receptor antagonism, a new sleep-enabling paradigm: A proof-of-concept clinical trial. Clin Pharmacol Ther. 2012;91:975-85.
11. Hoever P, de Haas SL, Dorffner G, Chiossi E, van Gerven JM, Dingemanse J. Orexin receptor antagonism: an ascending multiple-dose study with almorexant. J Psychopharmacol. 2012;26:1071-80.
12. Hoch M, Hoever P, Zisowsky J, Priestley A, Fleet D, Dingemanse J. Absolute oral bioavailability of almorexant, a dual orexin receptor antagonist, in healthy human subjects. Pharmacology. 2012;89:53-7.
13. Bjornsson TD, Callaghan JT, Einolf HJ, Fischer V, Gan L, Grimm S, Pharmaceutical Research and Manufacturers of America (PhRMA) Drug Metabolism/Clinical Pharmacology Technical Working Group; FDA Center for Drug Evaluation and Research (CDER), et al. The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. Drug Metab Dispos. 2003;31:815-32. (Pubitemid 36759050)
14. Hoch M, Hoever P, Alessi F, Theodor R, Dingemanse J. Pharmacokinetic interactions of almorexant with midazolam and simvastatin, two CYP3A4 model substrates, in healthy male subjects. Eur J Clin Pharmacol. 2013;69:523-32.
15. Holford NH. Clinical pharmacokinetics and pharmacodynamics of warfarin. Understanding the dose-effect relationship. Clin Pharmacokinet. 1986;11:483-504. (Pubitemid 17203070)
16. Kaminsky LS, Zhang ZY. Human P450 metabolism of warfarin. Pharmacol Ther. 1997;73:67-74. (Pubitemid 26425815)
17. Sullivan DM, Ford MA, Boyden TW. Grapefruit juice and the response to warfarin. Am J Health Syst Pharm. 1998;55:1581-3. (Pubitemid 28405996)
18. Mohammed Abdul MI, Jiang X, Williams KM, Day RO, Roufogalis BD, Liauw WS, et al. Pharmacodynamic interaction of warfarin with cranberry but not with garlic in healthy subjects. Br J Pharmacol. 2008;154:1691-700.
19. Ouellet D, Bramson C, Carvajal-Gonzalez S, Roman D, Randinitis E, Remmers A, et al. Effects of lasofoxifene on the pharmacokinetics and pharmacodynamics of single-dose warfarin. Br J Clin Pharmacol. 2006;61:741-5. (Pubitemid 43794804)
20. Draft Guidance for Industry. Drug interaction studies - study design, data analysis, implications for dosing and labeling recommendations. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER); 2012.
21. Malhotra B, Alvey C, Gong J, Li X, Duczynski G, Gandelman K. Effects of fesoterodine on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers. Br J Clin Pharmacol. 2011;72:257-62.
22. Hoch M, Hoever P, Theodor R, Dingemanse J. Almorexant effects on CYP3A4 activity studied by its simultaneous and time-separated administration with simvastatin and atorvastatin. Eur J Clin Pharmacol. 2013;69:1235-45.